Xilio Therapeutics Inc <XLO.OQ> expected to post a loss of 16 cents a share - Earnings Preview

• Xilio Therapeutics Inc XLO.OQ XLO.O is expected to show a rise in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025

• The Waltham Massachusetts-based company is expected to report a 214.0% increase in revenue to $7.4 million from $2.36 million a year ago, according to the estimate from one analyst, based on LSEG data.

• ​LSEG's mean analyst estimate for Xilio Therapeutics Inc is for a loss of 16 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts had risen by about 170.4% in the last three months. ​

• Wall Street's median 12-month price target for Xilio Therapeutics Inc is $4.00​, above​ its last closing price of $0.72. ​​​

This summary was machine generated May 9 at 13:51 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)